Effect of PARP on apoptosis and proliferation in androgen dependent prostate cancer LNCaP cells
10.3760/cma.j.issn.1000-6702.2011.12.018
- VernacularTitle:多聚腺苷二磷酸核糖聚合酶在前列腺癌LNCaP细胞株中的表达及意义
- Author:
Wenqi WU
;
Shaohua ZENG
;
Shujue LI
;
Yeping LIANG
;
Lili OU
;
Guohua ZENG
- Publication Type:Journal Article
- Keywords:
Prostatic neoplasms;
Carcinoma;
Poly (ADP-ribose) oiktnerase;
Inhibition;
Proliferation
- From:
Chinese Journal of Urology
2011;32(12):839-842
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the expression of PARP and its effect on apoptosis and proliferation in androgen dependent prostate cancer LNCaP cells.Methods The expression of PARP in a LNCaP cell line with or without PARP inhibitor 5-AIQ was measured by Western blot.The effect of 5-AIQ on the proliferation of LNCaP cells was analyzed with MTS assay,and flow cytometry analysis was performed to assess the apoptosis of LNCAP cells induced by 5-AIQ treatments.Results The protein expression of PARP in LNCaP cell line decreased to 65.3％ or 22.4％ in the 5-AIQ treatment group (500 μmol/L or 1000 μmol/L) respectively,which was obviously suppressed compared with the blank group ( P ＜ 0.05 ).When 5-AIQ was applied,from 200 to 1000 μ mol/L,the inhibition ratio of the proliferation of LNCaP cells was increased from (2.85±2.03)％ to (41.23 ±5.42)％,(2.85 ±2.03)％ to (41.23 ±5.42)％,or (25.67 ±0.63 ) ％ to (65.81 ± 1.62 ) ％ after treatment for 24 h,48 h and 72 h.The growth of LNCaP cells was significantly inhibited compared with the blank group in a dose-time-effect relationship ( P ＜ 0.05 ).Flow cytometry analysis showed that the number of apoptosis cells in early,late and total phase induced by different doses (500 μ mol/L or 1000 μmol/L) of 5-AIQ after 48 h were 23.6％,4.6％,28.2％ and 31.8％,6.3 ％,38.1％ respectively,which was significantly higher than those in the blank group ( P ＜ 0.05 ).Conclusions The expression of PARP in LNCaP cell line was suppressed by PARP inhibitor 5-AIQ,which can both inhibit proliferation and induce apoptosis of the LNCaP cell line.PARP is expected to become a new therapeutic target for prostate cancer in the future.
